Lei Chen
陈磊
elsewhere's corpus does not cover a single, clearly identified "Lei Chen." The name appears in at least two distinct people across the material: **Chen Lei** (陈磊), founder and chairman of biotech firm **Zhongsheng Quanpeptide** (中晟全肽), which raised over 300 million yuan in Series C funding as of May 2025 and had secured a global licensing deal with a multinational pharma company worth nearly $70 million upfront ; and a separate **Chen Lei** (陈磊), a Tsinghua University master's student in "excavated documents and Chinese history" born after 2000, who is also described as running an AI startup and contributed to a Y Transformers discussion on model overfitting in April 2026 . No relation between these two individuals is indicated in the corpus.
AI-generated — may contain errors, please verify.
Coverage
"Zhongsheng Quanpeptide" Raises Over 300 Million Yuan in Series C Funding to Accelerate Global Expansion of Peptide-Based Innovative Drugs
It has secured multiple international partnerships with MNCs including Novartis and Eli Lilly and Company.
高榕创投·What Real AI Problems Did Post-'98 Founders Debug Over Hot Pot? | Y Transformers Beijing Recap
The hot pot bubbles, but the thinking bubbles even more.
云启资本·Beyond the Code: Do Liberal Arts Majors Still Have a Seat at the Table in the AI Era? | Yunqi Capital Tech Notes
Every way of thinking could connect to the future.
云启资本·
